News

The two Cambridge-based biotech companies are seeking approval for plans to raise their stock prices and avoid being delisted. Click here to view original post… […]

Students working in Boston Medical Center’s Autism Program make an impact while experiencing the whirlwind atmosphere of a hospital. Click here to view original post… […]

Ming Guo seeks connections between a cell’s physical form and its biological function, which could illuminate ways to halt abnormal cell growth. Click here to view original post… […]

WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian… Click here to view original post… […]

Steven Wofsy explains how the satellite will spot global sources of methane emissions, which in many cases can be halted with relatively simple fixes. Click here to view original post… […]

An eating plan developed by researchers at Harvard T.H. Chan School of Public Health recently been touted for its potential to promote healthy aging Click here to view original post… […]

Developed at SMART, the therapy stimulates the host immune system to more effectively clear bacterial infections and accelerate infected wound healing. Click here to view original post… […]

Form D Friday is a Boston Business Journal feature highlighting regulatory filings from Boston-area companies raising capital for new projects or expanding their businesses. Click here to view original post… […]

The FDA’s Oncology Center of Excellence has been a bright spot within the agency in terms of speeding new treatments to patients. That flexibility was on full display this morning as FDA released new draft guidance spelling out exactly how oncology drug developers can fulfill both… Click here to view original post… […]

CAMBRIDGE, Mass., March 24, 2023 /PRNewswire/ — Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that it has filed a revised definitive proxy statement with the Securities and… Click here to view original post… […]